95% effective dose of dexmedetomidine in percutaneous kyphoplasty

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060090

Enrollment

Unknown

Registered

2022-05-18

Start date

2022-05-20

Completion date

Unknown

Last updated

2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

experimental group:Dexmedetomidine

Eligibility

Sex/Gender

All

Age

65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 65-90 years; 2. Patients undergoing intravenous anesthesia for percutaneous kyphoplasty; 3. Patients with ASA grade I-III; 4. Agree to participate in this study and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with preoperative bradycardia (HR less than 60 times/min) liver and kidney insufficiency, stroke, cerebral hemorrhage, infectious diseases, and immune system diseases; 2. Patients with delirium, cognitive dysfunction and other mental diseases before surgery; 3. Patients with serious mental illness.

Design outcomes

Primary

Measure	Time frame
95% effective dose of dexmedetomidine in percutaneous kyphoplasty;	—

Countries

China

Contacts

Public ContactShu Shiyu

shushiyu@hotmail.com+86 18917785284

Outcome results